BlackRock Fund Advisors has recently announced that it has increased stake in Cymabay Therapeutics Inc (NASDAQ:CBAY) by 5.53%. After grabbing 7.0 million shares, the institutional investor is now in possession of 0.37 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 6.21% having worth around $114.63 million. Moreover, RA Capital Management LP increased its share by 6.94 million to have a control over 6.94 million shares. And The Vanguard Group, Inc. raised its holdings to 0.59 million shares by acquiring 5.49 million shares or 4.87% of the stake.
Cymabay Therapeutics Inc (CBAY) concluded trading on 12/14/23 at a closing price of $21.64, with 4.02 million shares of worth about $86.89 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 157.31% during that period and on Thursday the price saw a gain of about 1.26%. Currently the company’s common shares owned by public are about 113.40M shares, out of which, 108.18M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 62 times over the past 12 months. They bought 585,559 shares in 31 of the transactions. In 31 selling transactions, insiders dumped 518,514 shares.
Vanguard Total Stock Market ETF, iShares Russell 2000 ETF, and FTIF SICAV – Biotechnology Discov are the top 3 mutual funds which are holding stakes in Cymabay Therapeutics Inc Vanguard Total Stock Market ETF is currently holding 3.47 million shares of worth totaling $56.8 million. The company recently came buying 8331.0 shares which brought its stake up to 3.08% of the company’s outstanding shares. iShares Russell 2000 ETF sold 22833.0 shares, after which its hold over company’s outstanding shares shrunk to 2.02%, leaving 2.27 million shares with the mutual fund that have a worth of about $37.24 million. FTIF SICAV – Biotechnology Discov, after buying 1.7 million shares, have now control over 1.51% of the stake in the company. It holds 0.0 shares of worth $27.85 million.
However, the stock later moved at a day high price of 21.87, or with a gain of 1.26%. Stock saw a price change of -0.60% in past 5 days and over the past one month there was a price change of 25.81%. Year-to-date (YTD), CBAY shares are showing a performance of 245.14% which increased to 430.39% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.03 but also hit the highest price of $21.92 during that period. The average intraday trading volume for Cymabay Therapeutics Inc shares is 1.95 million. The stock is currently trading 11.11% above its 20-day simple moving average (SMA20), while that difference is up 28.67% for SMA50 and it goes to 74.09% higher than SMA200.
BlackRock Fund Advisors acquired 7.0 million shares of Cymabay Therapeutics Inc having value of about $114.63 million. Data submitted at the U.S SEC by BlackRock Fund Advisors revealed that the firm now holds 0.37 million shares in the company valued at close to $7933483.68, or have control over 5.53% stake in the company. Cymabay Therapeutics Inc (NASDAQ: CBAY) currently have 113.40M outstanding shares and institutions hold larger chunk of about 93.28% of that. Holding of mutual funds in the company is about 61.91% while other institutional holders and individual stake holders have control over 9.65% and 31.99% of the stake respectively.
The stock has a current market capitalization of $2.45B and its 3Y-monthly beta is at 0.27. It has posted earnings per share of -$0.93 in the same period. It has Quick Ratio of 22.76 while making debt-to-equity ratio of 0.32. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CBAY, volatility over the week remained 6.37% while standing at 5.76% over the month.
Analysts are in expectations that Cymabay Therapeutics Inc (CBAY) stock would likely to be making an EPS of $CymaBay Therapeutics Inc. in the current quarter, while forecast for next quarter EPS is $21.64 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $CBAK Energy Technology, Inc. which is $Ceridian HCM Holding Inc. at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $Colony Bankcorp, Inc. in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 22.80% while it is estimated to decrease by -44.90% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on August 14, 2023 offering a Buy rating for the stock and assigned a target price of $18 to it.
